Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells

Scandinavian Journal of Immunology

Volumn 66, Issue 5, 2007, Pages 546-554

  Ishida, A ^a   Tanaka, H ^a   Hiura, T ^a   Miura, S ^a   Watanabe, S ^a   Matsuyama, K ^a   Kuriyama, H ^a   Tanaka, J ^a   Kagamu, H ^a,b   Gejyo, F ^a   Yoshizawa, H ^a,b  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CANCER VACCINE; CD69 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; L SELECTIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL LINE; CELL SECRETION; CELL STIMULATION; COCULTURE; CONCENTRATION (PARAMETERS); DENDRITIC CELL; DOWN REGULATION; EFFECTOR CELL; ELECTROFUSION (CELL); FEMALE; GENETIC TRANSFECTION; IMMUNOGENICITY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; TUMOR CELL; UPREGULATION;

ANIMALS; CELL FUSION; CELL LINE, TUMOR; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HYBRID CELLS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES;

EID: 35349028375     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.02012.x     Document Type: Article

References (44)

1. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991 254 : 1643 7.
2. Lee PP, Yee C, Savage PA et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999 5 : 677 85.
3. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004 350 : 1461 3.
4. Boon T, Van den Eynde B. Tumour immunology. Curr Opin Immunol 2003 15 : 129 30.
5. Yoshizawa H, Sakai K, Chang AE et al. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell Immunol 1991 134 : 473 9.
6. Yoshizawa H, Chang AE, Shu S. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells. Cancer Res 1992 52 : 1129 36.
7. Peng L, Shu S, Krauss JC. Treatment of subcutaneous tumor with adoptively transferred T cells. Cell Immunol 1997 178 : 24 32.
8. Plautz GE, Touhalisky JE, Shu S. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell Immunol 1997 178 : 101 7.
9. Chang AE, Yoshizawa H, Sakai K et al. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 1993 53 : 1043 50.
10. Chang AE, Aruga A, Cameron MJ et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997 15 : 796 807.
11. Inaba K, Inaba M, Romani N et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992 176 : 1693 702.
12. Steinman RM, Turley S, Mellman I et al. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000 191 : 411 6.
13. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004 104 : 2235 46.
14. Bell D, Chomarat P, Broyles D et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999 190 : 1417 26.
15. Almand B, Resser JR, Lindman B et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000 6 : 1755 66.
16. Tanaka H, Yoshizawa H, Yamaguchi Y et al. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells. J Immunol 1999 162 : 3574 82.
17. Fujita N, Kagamu H, Yoshizawa H et al. CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells. J Immunol 2001 167 : 5678 88.
18. Hayashi T, Tanaka H, Tanaka J et al. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 2002 104 : 14 20.
19. Tanaka H, Shimizu K, Hayashi T et al. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 2002 220 : 1 12.
20. Kjaergaard J, Shimizu K, Shu S. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 2003 225 : 65 74.
21. Shimizu K, Kuriyama H, Kjaergaard J et al. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 2004 27 : 265 72.
22. Parkhurst MR, DePan C, Riley JP et al. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 2003 170 : 5317 25.
23. Raje N, Hideshima T, Davies FE et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol 2004 125 : 343 52.
24. Avigan D, Vasir B, Gong J et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004 10 : 4699 708.
25. Hart IR. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 1979 97 : 587 600.
26. Shu SY, Rosenberg SA. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res 1985 45 : 1657 62.
27. Kagamu H, Shu S. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol 1998 160 : 3444 52.
28. Gong J, Nikrui N, Chen D et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 2000 165 : 1705 11.
29. Gong J, Avigan D, Chen D et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci U S A 2000 97 : 2715 8.
30. Dummer W, Niethammer AG, Baccala R et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 2002 110 : 185 92.
31. Kjaergaard J, Peng L, Cohen PA et al. Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells. Clin Immunol 2003 108 : 8 20.
32. Mule JJ, Ettinghausen SE, Spiess PJ et al. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. Cancer Res 1986 46 : 676 83.
33. Yee C, Thompson JA, Byrd D et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002 99 : 16168 73.
34. Ho WY, Nguyen HN, Wolfl M et al. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire. J Immunol Methods 2006 310 : 40 52.
35. De Vries IJ, Krooshoop DJ, Scharenborg NM et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003 63 : 12 7.
36. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 2002 99 : 351 8.
37. Dhodapkar MV, Steinman RM, Krasovsky J et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001 193 : 233 8.
38. Watanabe S, Kagamu H, Yoshizawa H et al. The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity. J Immunol 2003 171 : 5828 36.
39. Benvenuti F, Lagaudriere-Gesbert C, Grandjean I et al. Dendritic cell maturation controls adhesion, synapse formation, and the duration of the interactions with naive T lymphocytes. J Immunol 2004 172 : 292 301.
40. Gattinoni L, Klebanoff CA, Palmer DC et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005 115 : 1616 26.
41. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005 23 : 2346 57.
42. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982 155 : 1063 74.
43. Ercolini AM, Ladle BH, Manning EA et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005 201 : 1591 602.
44. Beyer M, Kochanek M, Darabi K et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005 106 : 2018 25.